230 related articles for article (PubMed ID: 16420051)
1. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis.
Petros AM; Dinges J; Augeri DJ; Baumeister SA; Betebenner DA; Bures MG; Elmore SW; Hajduk PJ; Joseph MK; Landis SK; Nettesheim DG; Rosenberg SH; Shen W; Thomas S; Wang X; Zanze I; Zhang H; Fesik SW
J Med Chem; 2006 Jan; 49(2):656-63. PubMed ID: 16420051
[TBL] [Abstract][Full Text] [Related]
2. Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.
Wendt MD; Shen W; Kunzer A; McClellan WJ; Bruncko M; Oost TK; Ding H; Joseph MK; Zhang H; Nimmer PM; Ng SC; Shoemaker AR; Petros AM; Oleksijew A; Marsh K; Bauch J; Oltersdorf T; Belli BA; Martineau D; Fesik SW; Rosenberg SH; Elmore SW
J Med Chem; 2006 Feb; 49(3):1165-81. PubMed ID: 16451081
[TBL] [Abstract][Full Text] [Related]
3. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft.
Zhang YH; Bhunia A; Wan KF; Lee MC; Chan SL; Yu VC; Mok YK
J Mol Biol; 2006 Dec; 364(3):536-49. PubMed ID: 17011577
[TBL] [Abstract][Full Text] [Related]
4. Fragment-based deconstruction of Bcl-xL inhibitors.
Barelier S; Pons J; Marcillat O; Lancelin JM; Krimm I
J Med Chem; 2010 Mar; 53(6):2577-88. PubMed ID: 20192224
[TBL] [Abstract][Full Text] [Related]
5. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions.
Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH
J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293
[TBL] [Abstract][Full Text] [Related]
6. Targeting the BH3 domain mediated protein-protein interaction of Bcl-xL through virtual screening.
Mukherjee P; Desai P; Zhou YD; Avery M
J Chem Inf Model; 2010 May; 50(5):906-23. PubMed ID: 20392095
[TBL] [Abstract][Full Text] [Related]
7. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
Bruncko M; Oost TK; Belli BA; Ding H; Joseph MK; Kunzer A; Martineau D; McClellan WJ; Mitten M; Ng SC; Nimmer PM; Oltersdorf T; Park CM; Petros AM; Shoemaker AR; Song X; Wang X; Wendt MD; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
J Med Chem; 2007 Feb; 50(4):641-62. PubMed ID: 17256834
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and interaction study of quinazoline-2(1H)-thione derivatives as novel potential Bcl-xL inhibitors.
Feng Y; Ding X; Chen T; Chen L; Liu F; Jia X; Luo X; Shen X; Chen K; Jiang H; Wang H; Liu H; Liu D
J Med Chem; 2010 May; 53(9):3465-79. PubMed ID: 20405848
[TBL] [Abstract][Full Text] [Related]
9. Isolation of a small-molecule inhibitor of the antiapoptotic protein Bcl-xL from a DNA-encoded chemical library.
Melkko S; Mannocci L; Dumelin CE; Villa A; Sommavilla R; Zhang Y; Grütter MG; Keller N; Jermutus L; Jackson RH; Scheuermann J; Neri D
ChemMedChem; 2010 Apr; 5(4):584-90. PubMed ID: 20229565
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and computational studies of inhibitors of Bcl-XL.
Park CM; Oie T; Petros AM; Zhang H; Nimmer PM; Henry RF; Elmore SW
J Am Chem Soc; 2006 Dec; 128(50):16206-12. PubMed ID: 17165773
[TBL] [Abstract][Full Text] [Related]
11. A new assay for the discovery of Bcl-XL inhibitors.
Pisoni C; Cimoli G; Resconi A; Losi D; Lorenzetti R; Parodi S; Carrano L
Farmaco; 2005; 60(11-12):938-43. PubMed ID: 16054143
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship studies of phenanthridine-based Bcl-XL inhibitors.
Bernardo PH; Wan KF; Sivaraman T; Xu J; Moore FK; Hung AW; Mok HY; Yu VC; Chai CL
J Med Chem; 2008 Nov; 51(21):6699-710. PubMed ID: 18925736
[TBL] [Abstract][Full Text] [Related]
13. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies.
Petros AM; Nettesheim DG; Wang Y; Olejniczak ET; Meadows RP; Mack J; Swift K; Matayoshi ED; Zhang H; Thompson CB; Fesik SW
Protein Sci; 2000 Dec; 9(12):2528-34. PubMed ID: 11206074
[TBL] [Abstract][Full Text] [Related]
14. Photocontrollable peptide-based switches target the anti-apoptotic protein Bcl-xL.
Kneissl S; Loveridge EJ; Williams C; Crump MP; Allemann RK
Chembiochem; 2008 Dec; 9(18):3046-54. PubMed ID: 19012295
[TBL] [Abstract][Full Text] [Related]
15. Deciphering the antitumoral activity of quinacrine: Binding to and inhibition of Bcl-xL.
Orzáez M; Mondragón L; García-Jareño A; Mosulén S; Pineda-Lucena A; Pérez-Payá E
Bioorg Med Chem Lett; 2009 Mar; 19(6):1592-5. PubMed ID: 19237284
[TBL] [Abstract][Full Text] [Related]
16. Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL.
Yin H; Lee GI; Sedey KA; Kutzki O; Park HS; Orner BP; Ernst JT; Wang HG; Sebti SM; Hamilton AD
J Am Chem Soc; 2005 Jul; 127(29):10191-6. PubMed ID: 16028929
[TBL] [Abstract][Full Text] [Related]
17. Identification of lead compounds as antagonists of protein Bcl-xL with a diversity-oriented multidisciplinary approach.
Di Micco S; Vitale R; Pellecchia M; Rega MF; Riva R; Basso A; Bifulco G
J Med Chem; 2009 Dec; 52(23):7856-67. PubMed ID: 19852471
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
Doshi JM; Tian D; Xing C
J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR.
Petros AM; Huth JR; Oost T; Park CM; Ding H; Wang X; Zhang H; Nimmer P; Mendoza R; Sun C; Mack J; Walter K; Dorwin S; Gramling E; Ladror U; Rosenberg SH; Elmore SW; Fesik SW; Hajduk PJ
Bioorg Med Chem Lett; 2010 Nov; 20(22):6587-91. PubMed ID: 20870405
[TBL] [Abstract][Full Text] [Related]
20. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.
Shoemaker AR; Oleksijew A; Bauch J; Belli BA; Borre T; Bruncko M; Deckwirth T; Frost DJ; Jarvis K; Joseph MK; Marsh K; McClellan W; Nellans H; Ng S; Nimmer P; O'Connor JM; Oltersdorf T; Qing W; Shen W; Stavropoulos J; Tahir SK; Wang B; Warner R; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
Cancer Res; 2006 Sep; 66(17):8731-9. PubMed ID: 16951189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
